World Pharma News

Labour on collision course with big pharma over drugs

Labour on collision course with big pharma over drugs
 

Labour’s newly announced policy on research funding for new medicines raises big questions about the balance between private profit and public good.

The party wants to make big drug companies hand over their exclusive research details so medicines can be made and sold more cheaply by others.

Should major drug companies have the right to benefit from their research investment through exclusive rights to sell new products over a decade or more?

Or should the government have the right to over-ride that when certain potentially life-changing medicines are deemed too expensive for NHS patients?

It was not surprising Jeremy Corbyn chose the example of the cystic-fibrosis drug Orkambi.

It has been a high profile and long-running saga, with NHS England and the National Institute for Health and Care Excellence unable to agree a deal with the manufacturer, Vertex.

Cystic fibrosis drug decision ‘heartbreaking’

Cheaper NHS drugs ‘as safe and effective’

The official listed price is more than £100,000 per year per patient, though the company has indicated it would be prepared to negotiate and the Scottish government has reached an agreement to purchase and supply the drug.

Mr Corbyn referred to the case of nine-year-old Luis Walker, who has four hours of treatment a day but whose life might be very different with Orkambi.

He said: “Luis, and tens of thousands of others suffering from illnesses such as cystic fibrosis, hepatitis C and breast cancer, are being denied life-saving medicines by a system that puts profits for shareholders before people’s lives.”

What is Labour planning to do if elected?

In essence, Labour wants to over-ride, in some circumstances, the patent system that allows drug companies to prevent others from replicating their new products over a defined period of 10 years or more.

A patent typically lasts 20 years in total, though this includes the time to complete trials and get regulatory approval.

The Labour leader made this pledge: “We will create a new publicly owned generic drugs manufacturer to supply cheaper medicines to our NHS, saving our health service money and saving lives.”

The policy would utilise an existing but rarely used power to create what is known as a Crown use licence.

This would grant a state-owned company access to a drug company’s intellectual property in return for a relatively low payment.

Labour’s policy document refers to a recent German court decision to award a compulsory licence on an HIV drug and a similar move in Malaysia for a hepatitis C treatment.

The other strand of the Labour policy would ensure taxpayers benefited from new drugs developed by big companies in collaboration with public research bodies.

Some new medicines brought to market by the companies are based on initial research by other organisations.

 Labour’s newly announced policy on research funding for new medicines raises big questions about the balance between private profit and public good.

The party wants to make big drug companies hand over their exclusive research details so medicines can be made and sold more cheaply by others.

Should major drug companies have the right to benefit from their research investment through exclusive rights to sell new products over a decade or more?

Or should the government have the right to over-ride that when certain potentially life-changing medicines are deemed too expensive for NHS patients?

It was not surprising Jeremy Corbyn chose the example of the cystic-fibrosis drug Orkambi.

It has been a high profile and long-running saga, with NHS England and the National Institute for Health and Care Excellence unable to agree a deal with the manufacturer, Vertex.

Cystic fibrosis drug decision ‘heartbreaking’

Cheaper NHS drugs ‘as safe and effective’

The official listed price is more than £100,000 per year per patient, though the company has indicated it would be prepared to negotiate and the Scottish government has reached an agreement to purchase and supply the drug.

Mr Corbyn referred to the case of nine-year-old Luis Walker, who has four hours of treatment a day but whose life might be very different with Orkambi.

He said: “Luis, and tens of thousands of others suffering from illnesses such as cystic fibrosis, hepatitis C and breast cancer, are being denied life-saving medicines by a system that puts profits for shareholders before people’s lives.”

 

ΠΗΓΗ : BBC

 

Διαβάστε όλες τις τελευταίες Ειδήσεις για την υγεία από την Ελλάδα και τον Κόσμο

Διαβάστε Eπίσης:

Hardo Fischer exclusively on healthweb: Gene therapies introduce new therapeutic model in Medicine

‘AeroNabs’ promise powerful, inhalable protection against COVID-19

The Health Economy: A Strengthening and Stabilizing factor for Economic Development

Dr. Emmanuel Alexandrakis is a Global Market Strategist at the WifOR Institute, a German independent Economic Research Organization, and Adjunct Professor at the MBA International Program of the Athens University of Economics and Business for Health Sector Strategy. The recent global crisis, that was triggered by the COVID-19 pandemic, underlined the importance of investing in the health sector. The unprecedented effects of this global pandemic, […]

How risky is it to attend a Trump campaign rally during a pandemic?

As the coronavirus plows through the United States, health experts worry President Donald Trump’s campaign rally in Tulsa, Oklahoma, will become a new hotspot for coronavirus infections. Leaders and public health experts have expressed concern, including Dr. Anthony Fauci, the nation’s top infectious disease expert, as well as Bruce Dart, the director of Tulsa’s health […]

Trump officials deflect blame for US death toll, escalate reopening push

Analysis by Stephen Collinson, CNN N)Two of President Donald Trump’s top officials are now pointing the finger at the administration’s own scientists and Americans’ pre-existing health conditions to explain the country’s world-leading Covid-19 death toll. Health and Human Services Secretary Alex Azar suggested Sunday that underlying health conditions, including among minorities, were one reason for the high American […]

Coronavirus Q&As for Consumers

The FDA is working to address the coronavirus disease (COVID-19) outbreak and keep you and your family informed on the latest developments. Here are answers to some frequently asked questions from consumers about treatments and prevention:   Q: Are antibiotics effective in preventing or treating COVID-19?   A: No. Antibiotics do not work against viruses; […]

Trump bans export of coronavirus protection gear, says he’s ‘not happy with 3M’

President Donald Trump on Friday invoked the Defense Production Act to ban “unscrupulous actors and profiteers” from exporting critical medical gear used to protect wearers from the coronavirus. The president unveiled the new order amid a dispute with U.S. manufacturing giant 3M, which had warned the Trump administration that halting its exports of respirator masks could make them even […]

WHO warns of global medical equipment shortage as world braces for coronavirus spread

Countries worldwide are preparing for the possibility of public health emergencies related to the novel coronavirus, as the World Health Organization warned a shortage of protective equipment is hampering the response to the outbreak. The virus has infected more than 92,800 people and killed at least 3,200 since it was first identified in the Chinese […]

Scottish Academy launches ‘bold’ strategic priorities

by Anna Smith The Academy of Medical Royal Colleges and Faculties in Scotland (the Scottish Academy) has published its strategic priorities to 2023, outlining a focus on collaborative working between the different medical professions in Scotland, to “improve quality of care for patients.” The Academy, which promotes and co-ordinates the work of the Medical Royal Colleges […]

MHRA updates Dysport license to include upper limb spasticity in children

By Anna Smith The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Ipsen a licence update for Dysport (abobotulinumtoxinA), extending the use of the drug to focal spasticity of upper limbs in paediatric cerebral palsy (CP) patients, two years of age or older. The regulatory body says that the approval was based on a […]